Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification

Saarang Panchavati | Carson Lam | Nicole S. Zelin | Emily Pellegrini | Gina Barnes | Jana Hoffman | Anurag Garikipati | Jacob Calvert | Qingqing Mao | Ritankar Das

Division of Data Science, Dascena, Inc., Houston, Texas, USA

Correspondence
Gina Barnes, 12333 Sowden Rd Ste B PMB 65148, Houston, Texas 77080-2059, USA.
Email: gbarnes@dascena.com

Abstract
Diagnosis and appropriate intervention for myocardial infarction (MI) are time-sensitive but rely on clinical measures that can be progressive and initially inconclusive, underscoring the need for an accurate and early predictor of MI to support diagnostic and clinical management decisions. The objective of this study was to develop a machine learning algorithm (MLA) to predict MI diagnosis based on electronic health record data (EHR) readily available during Emergency Department assessment. An MLA was developed using retrospective patient data. The MLA used patient data as they became available in the first 3 h of care to predict MI diagnosis (defined by International Classification of Diseases, 10th revision code) at any time during the encounter. The MLA obtained an area under the receiver operating characteristic curve of 0.87, sensitivity of 87% and specificity of 70%, outperforming the comparator scoring systems TIMI and GRACE on all metrics. An MLA can synthesize complex EHR data to serve as a clinically relevant risk stratification tool for MI.

1 BACKGROUND

In the United States, over 6.5 million patients annually are evaluated for chest pain in the Emergency Department (ED); in these instances, myocardial infarction (MI) is a key diagnostic consideration [1]. MI is defined as an acute myocardial injury indicated by elevated serum biomarkers of myocardial necrosis (typically cardiac troponins) with clinical evidence of acute myocardial ischemia [2]. 14% of people who suffer an MI in the United States die as a result [3]. Those who survive may experience significant morbidity and are at elevated risk for recurrent MI and death [4, 5]. Treatment outcomes are highly dependent on time-sensitive diagnosis and intervention, which aims to restore blood flow to ischemic myocardium to prevent or minimise tissue damage and death [6]. Indeed, the mortality risk is greatest in the earliest stages of an acute MI, underscoring the importance of rapid and accurate detection [3].

The diagnosis of MI is based on suggestive clinical signs and symptoms, electrocardiogram (ECG) abnormalities, and elevated cardiac troponins; cardiac imaging and stress tests may further assist in evaluation [7]. However, the diagnostic process is complicated by symptom variability across patient populations and overlap with the symptoms of other syndromes [8–10]. Up to one-third of MI are silent, or occurring without symptoms [11]. ECG abnormalities may be absent, progressive, or non-specific in the context of prior cardiac events and underlying ischemic disease [12]. While newer generation troponin tests and high sensitivity assays detect troponin elevation with great sensitivity even in the initial hours after symptom onset [13, 14], elevations are also detected in a range of other cardiac and non-cardiac conditions. MI encompasses both ST-elevation MI (STEMI) and Non-ST-elevation MI (NSTEMI). STEMI represent more severe ischemic events and are ideally recognised early in patient assessment based on the pathognomonic ST elevation on ECG. However, ED crowding has been identified as a potential challenge to delivering high quality care, including the timeliness of assessment [15, 16]. The ECG abnormalities in NSTEMI are variable and may be progressive, and NSTEMI cannot be distinguished from the related but less severe condition of unstable angina without evaluating cardiac troponins [9]. Patients, thus, may be boarded in the ED for prolonged periods and receive serial ECGs as...
well as troponin measurements at 3 or 6 h intervals [9]. ED length of stay may also be extended for patients with atypical symptom presentations during diagnostic work-up for MI and differential diagnoses [16]. Thus, enhanced risk stratification at 3 h represents a clinically relevant timeframe.

Diagnostic accuracy is also largely dependent on the diagnosing clinician, introducing further variability into the diagnostic process [17–19]. Amidst this complexity, it is perhaps unsurprising that the individual components of the standard clinical evaluation demonstrate limited accuracy for diagnosing MI, most notably in terms of sensitivity [20]. Clinical prediction tools, such as the thrombolysis in myocardial infarction (TIMI) score, may be used to help rule out MI or to determine the types of treatments appropriate for a patient’s estimated level of risk [20]. However, the uptake and routine use of these tools are constrained by their inherent interruption of the clinical workflow by relying on physicians to tabulate scores at the bedside or on a computer [21].

Delays in appropriate treatment are associated with increased mortality risks [9] and unnecessary treatment for MI can introduce treatment-related harms to improperly diagnosed patients [22] or lower-risk patients who could be treated with less intensive, guideline-recommended pharmacotherapies. These harms highlight the opportunity for innovative approaches to support MI diagnosis and treatment planning which are accurate, easy to integrate into the clinical workflow, and can be utilised within the initial hours of a patient’s assessment within the ED.

Machine learning (ML) approaches to the diagnosis and prediction of MI have been leveraged in a growing body of research, the preponderance of which focus on risk stratification or outcomes predictions following an MI [23, 24]. ML approaches to assist with specific steps in the initial diagnostic process have also been investigated, including approaches to improving ECG interpretation, identifying misplacement of ECG leads, and enhancing cardiac imaging capabilities to detect acute MI [25–27]. However, a Machine Learning Algorithm (MLA) based clinical decision support (CDS) tool that supports rapid rule in or rule out of MI, and provides actionable estimations of risk to guide the intensity of interventions, would improve care by minimising delays to individualised, risk-appropriate treatment. Ideally, such a tool would use data routinely available in the electronic health record (EHR) and would not require additional physician inputs so as not to impede the clinical workflow. Towards this end, we have developed a novel MLA that can predict MI using only data available within the first 3 h of a patient’s hospital-based assessment, and which does not require serial troponins or repeated ECG.

2 METHODS

2.1 Data processing

Patient data collected between 2011 and 2015 at a large academic medical center in the Western United States were used in this study. Data were extracted from patients admitted to any hospital ward and included patient demographics, past medical history, vital signs, and laboratory results. Data were collected passively and de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA).

For the purposes of this study, data was included from patients with at least one of each of the following measurements in the first 3 h of the patient encounter: systolic blood pressure, diastolic blood pressure, respiratory rate, peripheral oxygen saturation and troponin I. The requirement for a troponin measurement prior to the time point for algorithm deployment was included to ensure selection of a high-risk patient population in which MI was under diagnostic consideration. The information extracted by the MLA from the EHR to compute scores are presented in Table 1. Beyond a troponin measurement and the minimum vital sign measurements, no other features were explicitly required by the MLA to generate a prediction score, in order to maximise utility of the algorithm in live clinical environments in which different data may be available for different patients at the time of prediction generation.

The algorithm was designed to generate a score 3 h after the start of the patient encounter. Input features were added as they became available at a refresh rate of 10 min. If there were no new measurements after 10 min, measurements were carried forward. For timepoints at which a given measurement had not

| TABLE 1 Structure data extracted from the electronic health record if available in the patient record, used by the machine learning algorithm to predict myocardial infarction diagnosis |
|---------------------------------|---------------------------------|
| **Demographics**                |                                 |
| Age                             | Sex                             |
| **History of present illness**  |                                 |
| Chest pain                      |                                 |
| **Past medical history**        |                                 |
| Prior myocardial infarction     | Diabetes mellitus               |
| Hypertension                    | Hyperlipidemia                  |
| Tobacco use                     |                                 |
| **Vital signs**                 |                                 |
| Systolic blood pressure         | Diastolic blood pressure        |
| Heart rate                      | Respiratory rate                |
| Peripheral oxygen saturation (SpO2) | Temperature                   |
| **Laboratory values**           |                                 |
| Sodium                          | Troponin I                      |
| Potassium                       | Lactate                         |
| Blood urea nitrogen             | Hematocrit                      |
| Creatinine                      | Platelet count                  |
| Bicarbonate                     | White blood cell count          |
| Glucose                         | International normalised ratio (INR) |
| Aspartate transaminase          | Blood pH                        |
| Alanine transaminase            | Urine output                    |
| Total bilirubin                 |                                 |
been collected yet, a null value was reported and the null value was implicitly handled by the ML classifier as an input.

2.2 Gold standard

Encounters were considered positive for MI if an International Classification of Diseases (ICD), 10th revision (ICD-10) code for MI was listed for the encounter. The following ICD-10 codes were used to identify MI: I21.0, I21.1, I21.2, I21.3, I21.4, I22.0, I22.1, I22.2, I22.8, I22.9. ICD codes were used to define the positive class based on prior literature demonstrating that the codes perform with acceptable accuracy as proxies for MI diagnosis [28–34]. ICD codes have been shown to perform with high sensitivity, specificity, and positive predictive values in identifying MI within hospitalisation databases [28–30]. All patient encounters not labelled with one of the specified ICD-10 codes were considered negative. Whereas the MLA was only allowed to access to EHR data available within the first 3 h of an encounter for MI predictions, the gold standard could be established at any point during a patient’s ED assessment or subsequent hospitalisation.

2.3 Comparison to standard of care

The diagnostic evaluation of patients with suspected MI is composed of findings taken from the history of present illness, past medical history, physical exam, and diagnostic tests. Validated risk stratification tools may be used to integrate findings from these different sources to assist clinicians in predicting the likelihood that a given patient will experience an MI or associated major adverse outcomes. For this study, we chose to compare our MLA to two popular risk stratification tools for MI, the TIMI score and Global Registry of Acute Coronary Events (GRACE) score [34–36]. Based on clinical measurements taken at initial ED presentation, the GRACE score has been used to prognosticate outcomes such as MI and mortality during hospital admissions and periods of up to 3 years following admission [14]. The TIMI score also uses initial ED observation to prognosticate adverse outcomes related to cardiovascular morbidity. Both GRACE and TIMI scores are recommended by clinical societies to guide treatment planning decisions in the context of possible MI [14, 37]. Since this MLA was designed to serve as an alternative prognostication method in high risk patients, these common, guideline-recommended risk scores used to predict adverse cardiovascular outcomes were selected as comparators.

GRACE and TIMI translate key clinical findings into a final predictive score by weighting the findings and accumulating the numerical weights. Based on commonly cited cutoff points above which patients are no longer low risk for an MI and may be considered to be at elevated risk for an MI, the clinical operating points were defined as ≥2 for TIMI and ≥108 for GRACE [9, 38, 39]. The data necessary to tabulate TIMI and GRACE were not available for each unique encounter. To remedy this, we used a previously reported method to impute missing data which has also been used by other MLAs [40, 41]. ECG data were not available in this dataset and were thus not included in calculations of any TIMI or GRACE score; this impacted the maxima for each score. As the MLA produces probability scores ranging from 0 to 1, TIMI and GRACE scores were scaled into probability scores to facilitate comparison by dividing the score by the respective model’s maximum achievable score within our dataset (5.3 for TIMI, 305 for GRACE). Scaled scores were then plotted on receiver operating characteristic (ROC) curves. The original TIMI and GRACE risk scores inputs are provided in Supplementary Table 1. Data inputs used to tabulate the adjusted TIMI and GRACE are provided in Supplementary Table 2.

2.4 Machine learning algorithm

A novel MLA was developed to predict MI, trained using the inputs in Table 1. The MLA is a gradient boosted tree model implemented with the XGBoost (XGB) library in Python [42, 43]. The XGB method uses collections of gradient-boosted decision trees to classify data. For example, a patient’s creatinine level may place a patient along one of two paths. Using this example of creatinine, if this measurement is not available, the MLA would select a branching direction that results in the MLA making a better prediction on average. Multiple creatinine branching points may exist on a single decision tree with, for example, one that follows a male branching point and one that follows the female branching point, allowing two cutoff values for creatinine that are conditioned on the gender of the patient to exist. The end of the decision tree has one “leaf” that represents each patient encounter, with the patients in each leaf predicted to have the same probability of the outcome. The final score is then the sum of all trees. XGB models progressively incorporate any new splits in the branching points along the range of the values of its inputs, incorporating that information into new branches and new trees. Further, this training adjusts for the addition of any new component and how it may impact this component’s ability to reduce the loss function versus the contribution to the model’s general complexity. The objective or cost function, or the “loss function,” quantifies each new branch’s ability to improve the training accuracy after new branches are added to the model, and also to the model’s complexity and overfitting. Thus, weaker decision tree base learners adjust rapidly and effectively from large amounts of data, and learn even from missing data when using XGB. The XGB method was chosen for this study due to its simplicity, high performance, and useful implementation features, which provide options for handling imbalanced classes and regularisation [42, 44]. This model takes the first 3 h of data from Table 1 as input features, as data is made available, separated by 10 min intervals. As per the gold standard, patient encounters were labelled uniquely positive or negative, with encounters with MI defined as the positive class and those without as the negative class.

The model was trained and tested using an 80:20 train: test split. To train the model, 80% of patients were randomly
TABLE 2  Demographic information for the hold out test dataset used to test the machine learning algorithm

| Age (years) | Patients with MI ($n = 253$) | Patients without MI ($n = 1,600$) | $p$-values |
|-------------|-------------------------------|-----------------------------------|------------|
| <30         | 1 (0.4%)                      | 41 (2.6%)                         | 0.04       |
| 30–49       | 25 (9.9%)                     | 160 (10.0%)                       | 1.00       |
| 50–59       | 34 (13.4%)                    | 223 (13.9%)                       | 0.92       |
| 60–69       | 53 (20.9%)                    | 362 (22.6%)                       | 0.63       |
| 70–79       | 55 (21.7%)                    | 341 (21.3%)                       | 0.87       |
| <80         | 85 (33.6%)                    | 473 (29.6%)                       | 0.21       |
| Sex         |                               |                                   |            |
| Male        | 169 (66.8%)                   | 831 (51.9%)                       | 0.01       |
| Female      | 84 (33.2%)                    | 769 (48.1%)                       | 0.01       |
| Unknown     | 0 (0.0%)                      | 0 (0.0%)                          | 1.0        |
| Race        |                               |                                   |            |
| American Indian or Alaska Native | 0 (0.0%) | 0 (0.0%) | 1.0 |
| Asian       | 58 (22.9%)                    | 379 (23.7%)                       | 0.87       |
| Black or African American | 23 (9.1%) | 254 (15.9%) | 0.004 |
| Native Hawaiian or Other Pacific Islander | 9 (3.6%) | 33 (2.1%) | 0.17 |
| White or Caucasian | 116 (45.8%) | 703 (43.9%) | 0.59 |
| Other       | 43 (17.0%)                    | 211 (13.2%)                       | 0.11       |
| Unknown/declined | 4 (1.6%) | 20 (1.2%) | 0.56 |
| Ethnicity   |                               |                                   |            |
| Hispanic or Latino | 16 (6.3%) | 140 (8.8%) | 0.61 |
| Comorbid conditions |           |           |            |
| Obesity     | 13 (5%)                       | 143 (9%)                          | 0.05       |
| Diabetes mellitus | 108 (43%) | 516 (32%) | 0.001 |
| Dyslipidemia | 130 (51%)                     | 560 (35%)                         | < 0.001    |
| Hypertension | 201 (79%)                     | 1126 (70%)                        | 0.003      |
| Peripheral vascular disease | 28 (11%) | 69 (4%) | < 0.001 |
| Angina      | 52 (21%)                      | 96 (6%)                           | < 0.001    |
| Heart failure | 116 (46%)                     | 473 (30%)                         | < 0.001    |
| CKD         | 100 (40%)                     | 422 (26%)                         | < 0.001    |
| HIV infection and AIDS | 7 (3%) | 51 (3%) | 0.85 |
| Dementia    | 25 (10%)                      | 173 (11%)                         | 0.74       |
| COPD        | 35 (14%)                      | 314 (20%)                         | 0.03       |
| Depression  | 24 (9%)                       | 214 (13%)                         | 0.10       |
| Current tobacco use | 25 (10%) | 174 (11%) | 0.74 |
| Prior MI    | 61 (24%)                      | 148 (9%)                          | < 0.001    |
| Prior ischemic stroke or TIA | 2 (1%) | 20 (1%) | 0.76 |

Abbreviations: Acquired immunodeficiency syndrome (AIDS); chronic kidney disease (CKD); chronic obstructive pulmonary disease (COPD); human immunodeficiency virus (HIV); myocardial infarction (MI); transient ischemic attack (TIA).

selected and the remaining 20% were used as a hold-out set to test generalisation after training. A stratified threefold cross-validation grid search [45] was conducted for hyperparameter optimisation. The training set was split into 3 separate folds and each combination of hyperparameters was used to train the model on two folds and validate on the remaining one. The combination of hyperparameters that resulted in the highest validation AUC was saved as the optimal hyperparameters, which were then used to train the entire training set. Optimal hyperparameters included learning rate, regularisation penalty, positive weight scaling, and maximum tree depth. Final optimised hyperparameters for XGB were learning rate of 0.05, regularisation penalty of 3, positive weight scaling of 1, and maximum tree depth of 3.
Performance metrics are reported as the performance of the model on the testing set. Operating points for TIMI and GRACE were defined using the cutoff points described above. The operating point selected for the MLA along its ROC curve was selected to maximise sensitivity and specificity relative to the comparator models. Model performance at this operating point was compared to comparators’ performance at their respective operating points in terms of sensitivity, specificity, likelihood ratios and diagnostic odds ratios.

3 | RESULTS

We analysed 99,235 patient encounters, of which 9,265 encounters had at least 3 h of vital sign data recorded and at least one troponin-I test ordered during the encounter. The hold-out test set consisted of 1,853 patient encounters, of which 253 encounters were positive for MI per the gold standard (Figure 1).

All data presented below pertain to the hold out validation dataset used to test the MLA. Fisher’s exact test was used to evaluate statistical significance of demographic differences between patients with and without MI, with a significance level of $p < 0.05$. Patients who experienced an MI were less likely to be young and less likely to be female (Table 2). Significant differences in past medical history were noted between patients in the positive and negative classes, with MI patients more likely to have diabetes, hypertension, dyslipidemia, peripheral vascular disease, angina, heart failure, chronic kidney disease, and chronic obstructive pulmonary disease. Patients diagnosed with an MI were also more likely to have a history of prior MI. The median age for the MI population was 72 years (interquartile range (IQR): 60, 81), compared to 70 years (IQR: 58, 82) in the population without MI. Demographic data for the complete dataset used for training and testing is presented in Supplementary Table 3.

The MLA’s ability to predict MI was assessed on the hold out test dataset and compared to the adjusted TIMI and GRACE scores. ROC curves were plotted (Figure 2), with the MLA demonstrating superior performance in classifying cases compared to the clinical prediction rules.

The MLA outperformed the comparator tools in predicting MI on all metrics evaluated (Table 3). The MLA achieved an area under the receiver operating characteristic curve (AUROC) of 0.87, sensitivity of 0.87 and specificity of 0.70. The TIMI achieved an AUROC of 0.78 with a sensitivity of 0.84 and specificity of 0.57, performing better than the GRACE. GRACE demonstrated the lowest AUROC, sensitivity and specificity of the three models at 0.61, 0.78 and 0.33, respectively.

Feature correlations and distribution of feature importance for MLA performance was evaluated using a SHAP summary plot (Figure 3). Prior MI, troponin I values, and chest pain were among the most important EHR features for predicting MI. As expected, Troponin I values are positively correlated with MI. Rather than a single threshold for high versus low however, the model has multiple thresholds for troponin I conditioned on the patient’s other features. These thresholds can differ by branch or tree. In general, troponin I above the thresholds result in increases in the final score whereas troponin I below the thresholds result in decreases in the final score.

4 | DISCUSSION

Delays in appropriate treatment for MI are associated with increased mortality risks [9]. Conversely, unnecessary treatment (or unnecessarily aggressive treatment) can introduce treatment-related harms to improperly diagnosed patients [46], or lower-risk patients who could be treated with less intensive, guideline-recommended pharmacotherapies. These harms highlight the opportunity for innovative approaches to support MI risk stratification tools that are accurate, easy to integrate into the clinical workflow, and can be utilised within the initial hours of a patient’s assessment within the ED. In this work, we describe such a tool to support risk-appropriate medical intervention through timely and accurate risk stratification for MI among high-risk patients. Using the EHR database of a large academic medical center, an MLA was developed which could extract readily available data from EHRs as they were updated without interrupting the clinical workflow. The MLA was developed
to predict MI with high accuracy based on available inputs and outperformed clinical prediction tools which are currently suggested for risk stratification in clinical guidelines produced by the American Heart Association, American College of Cardiology [37] and the European Society of Cardiology [14].

The results of Table 3 demonstrate that the MLA performed substantially better than the TIMI and GRACE scores in predicting MI at any point during a patient encounter, achieving an AUROC of 0.87 compared to 0.78 for TIMI and 0.61 for GRACE. Notably, the tool was both more sensitive and more specific than the comparator risk stratification tools (Table 3; Supplementary Table 4). The MLA also achieved greater PPV and NPV than either GRACE or TIMI, indicating that it was more accurate in truly identifying high risk cases where MI ultimately occurred and correctly ruling out low risk cases in which MI did not occur. The MLA, thus, performed with high accuracy in predicting an eventual diagnosis of MI, using only the data available within an initial 3 h assessment window (Table 1). Unlike the more complex GRACE and TIMI scoring systems, which incorporate features that are not routinely assessed across patients (e.g. Killip class, 1 week history of aspirin use), the MLA is capable of making predictions using only routinely collected patient data, and therefore does not require additional work on the part of the clinician. Further, an MLA provides flexibility, as the operating point and/or threshold for alerts can be adjusted to reflect clinician feedback and to maximise the clinical utility of the tool to meet the needs of individual hospitals.

In addition to comparing performance to GRACE and TIMI, feature importance for all MLA inputs was assessed using SHAP values, which consider the contributions of each feature in making predictions (Figure 3). Past medical history of MI, Troponin I values, and chest pain were among the most important features for the MLA’s performance. Given the substantive research on chest pain as a cardinal symptom of MI, elevated troponin as a defining aspect of MI, and prior MI as a risk factor for recurrent MI, the MLA identified relevant relationships in the data consistent with the published literature [3, 39, 15].

The gold standard encompassed ICD-10 codes for both STEMI and NSTEMI, and was thus designed to predict both STEMI and NSTEMI. As described in the introduction, STEMI represent more severe ischemic events and are ideally recognised early in patient assessment, making enhanced risk stratification at 3 h a clinically relevant timeframe. Within the complete training and test dataset, an elevated troponin result was returned at a median of 2 h and mean of 7 h into the patient encounter. While this rough proxy for time of clinical diagnosis
does not take into account the time at which a clinician may first recognise suggestive ECG abnormalities, it does underscore the length of the diagnostic window for MI in a real-world setting and the utility of a CDS risk stratification tool which can facilitate hospitalisation and clinical management decisions within this window.

In the growing body of research on MLAs as CDS tools, these tools have performed with high sensitivity and specificity using variable types of input data [21]. However, many studies have been limited by training and testing in small sample populations, and some have required exhaustive inputs or additional manual data entry to make a prediction [21]. The MLA described in this work was trained and tested using a large dataset (n = 9,265) and minimal exclusion criteria were applied to maximise the generalisability of findings. Our MLA can extract and integrate multiple features from the EHR into predictions; however, beyond a single troponin measurement and at least one measurement for four routinely measured vital signs, the MLA does not require that any other individual feature be present in order to make a prediction. Previous researchers have suggested that incorporating troponin measurements into MLAs may enhance algorithms’ predictive ability [17]. In 2019, Than et al. reported on the prospective performance of the myocardial-ischemic-injury-index (MI3), a gradient boosted algorithm which uses patient demographics and two sequential high-sensitivity cardiac troponin values to predict likelihood of MI diagnosis [47]. MI3 demonstrated high sensitivity and specificity and was effective in ruling out patients without MI, with a NPV of 99.7% [47]. However, MI3 cannot make predictions without serial troponin measurements, which may not be readily available in an early assessment window in all clinical practice contexts [47]. The MLA we have developed can incorporate repeated troponin measurements as input features, but is not inhibited by their absence from making a prediction.

This work has several limitations. First, patient data were collected from a cohort of patients at a single academic medical center, which limits generalisability. Second, there was a higher percentage of male patients as compared to female patients among patients with MI in the hold out validation dataset. This sex-based difference may reflect existing bias in the diagnostic process for MI; recent research has suggested that lower troponin thresholds may be appropriate for diagnosing MI in women [12]. Third, while ICD codes for MI have been demonstrated to perform with high sensitivity, specificity, and positive predictive value for identifying MI in health records [28–30], it is possible that some patient encounters were not properly classified. In particular, some recent research in the era of high-sensitivity troponin tests has demonstrated a lack of concordance between ICD 10 labels and a clinical diagnosis of MI per the 4th Universal Definition of MI [48]. However, other studies using historical data have demonstrated acceptable concordance (e.g. kappa statistic $\kappa > 0.6$) between ICD codes for MI and clinician adjudicated diagnosis [31, 34]. As the data used in this study were collected in a comparable historical time period (2011–2015), ICD codes applied during this time period can be considered a reasonable proxy for clinical diagnosis. Fourth, the absence of ECG data in this dataset represents a limitation on the use of TIMI and GRACE as comparator models, as both scores incorporate ECG findings as inputs. The performance of the adjusted TIMI (AUROC = 0.78) and GRACE (AUROC = 0.61) in this study are largely consistent with previous research on unadjusted TIMI and GRACE scores to predict MI and other major adverse cardiovascular events in ED patients [49–51]. A further limitation on the use of the GRACE and TIMI scores as comparators is that neither tool was explicitly designed to only predict MI diagnosis within a hospital stay. However, both scores have been used to prognosticate cardiovascular adverse outcomes, such as MI, among patients at high risk of acute coronary syndrome, such that these clinical risk scores remain the most appropriate comparators for this novel MLA. Fifth, as this was a retrospective dataset provided via contract for research purposes, constraints on the breadth of data provided were present. For example, while the dataset indicated the timing of troponin test result, troponin test result in ng/mL, and whether a result was abnormal, no information on the type(s) or exact troponin assays used over the time period of the study were available. Finally, as this study was conducted retrospectively, future research on the prospective performance of this algorithm is warranted to support its utility as a CDS tool. In future work, this work will be extended by prospective assessment across data derived from different hospital settings, and investigate the use of sex-specific troponin cut-offs to improve diagnostic performance and utility of the tool in clinical practice.

5 | CONCLUSIONS

We have developed an MLA that can risk stratify patients for MI with high accuracy. Troponin remains an important input for the MLA, similar to standard MI clinical diagnostic and risk stratification tools, and future research directions may explore serial troponin as an input for this model in order to assess the impact on predictive accuracy. However, while our current MLA can incorporate repeated troponin measurements, only a single troponin measurement is required in order to make a prediction. As this MLA performs with high sensitivity and specificity, we propose that the use of a risk stratification MLA may support clinical management and hospitalisation decisions early in the diagnostic process.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Zohora Iqbal and Megan Handley for their assistance in editing this manuscript.

Declarations

Ethics Approval and Consent to Participate: Data were collected passively and de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA). Since data were de-identified and collected retrospectively, this study was considered non-human subjects research and did not require Institutional Review Board approval.
LIST OF ABBREVIATIONS

AUROC Area under the receiver operating characteristic curve
CDS Clinical decision support
DOR Diagnostic odds ratio
ECG Electrocardiogram
EHR Electronic health record
ED Emergency Department
GRACE Global Registry of Acute Coronary Events
HIPAA Health Insurance Portability and Accountability Act
ICD-10 International classification of diseases, 10th revision
IQR Interquartile range
LR Likelihood ratio
MLA Machine learning algorithm
MI Myocardial infarction
MI\textsuperscript{3} Myocardial-ischemic-injury-index
NPV Negative predictive value
NSTEMI Non-ST-elevation myocardial infarction
PPV Positive predictive value
ROC Receiver operating characteristic
STEMI ST-elevation myocardial infarction
TIMI Thrombolysis in Myocardial Infarction

ORCID

Emily Pellegrini https://orcid.org/0000-0001-7614-9299

REFERENCES

1. National Hospital Ambulatory Medical Care Survey: 2017 Emergency Department Summary Tables. (2017). https://www.cdc.gov/nchs/data/nhamcs/web_tables/2017_ed_web_tables-508.pdf. Accessed: 16 Sep 2020
2. Thygesen, K., et al.: Fourth universal definition of myocardial infarction (2018). Circulation 138(20), e618–e651 (2018)
3. Arora, G., Bittner, V.: Chest pain characteristics and gender in the early diagnosis of acute myocardial infarction. Curr. Cardiol. Rep. 17(2), 5 (2015)
4. Antman, E.M., Loscalzo, J.: ST-segment elevation myocardial infarction. In: Kasper, D., et al. (eds.) Harrison's Principles of Internal Medicine. 19th ed, McGraw-Hill Education, New York, NY (2014)
5. Smolina, K., et al.: Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ. Cardiovasc. Qual. Outcomes 5(4), 532–540 (2012)
6. Cannon, C.P., et al.: Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283(22), 2941–2947 (2000)
7. Smith, J.N., et al.: Diagnosis and management of acute coronary syndrome: an evidence-based update. J. Am. Board Fam. Med. 28(2), 283–293 (2015)
8. Barstow, C., Rice, M., McDvitt, J.D.: Acute coronary syndrome: Diagnostic evaluation. Am. Fam. Physician 95(3), 170–177 (2017)
9. Amsterdam, E.A., et al.: 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 64(24), e139–e228 (2014)
10. Patel, M.R., et al.: ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: A report of the American College of Cardiology appropriate use criteria task force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angleography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 69(5), 570–591 (2017)
11. Gibson, C.M., Naefe, T., Kerneis, M.: Silent myocardial infarction: Listen to the evidence. J. Am. Coll. Cardiol. 71(9), 9–11 (2018)
12. Romiti, G.F., et al.: Sex-specific cut-offs for high-sensitivity cardiac troponin: Is less more? Cardiovasc. Ther. 2019, 9546931 (2019)
13. Sandoval, Y., et al.: Single high-sensitivity cardiac Troponin I to rule out acute myocardial infarction. Am. J. Med. 130(9), 1076–1083e1 (2017)
14. Hindricks, G., et al.: 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42(5), 373–498 (2021)
15. Siegel, D., et al.: Risk factor modification after myocardial infarction. Ann. Intern. Med. 109(3), 213–218 (1988)
16. Morley, C., et al.: Emergency department crowding: A systematic review of causes, consequences and solutions. PLoS One 8(16), e203316 (2018)
17. Harrison, R.F., Kennedy, R.L.: Artificial neural network models for prediction of acute coronary syndromes using clinical data from the time of presentation. Ann. Emerg. Med. 46(5), 431–4 (2005)
18. Chen, S., et al.: Cardiac Troponin I in non-acute coronary syndrome patients with chronic kidney disease. PLoS One 8(12), e82725 (2013)
19. Patil, H., Vaidya, O., Bogart, D.: A review of causes and systemic approach to cardiac troponin elevation. Clin. Cardiol. 34(12), 723–728 (2011)
20. Fanaroff, A.C., et al.: Does this patient with chest pain have acute coronary syndrome? The rational clinical examination systematic review. JAMA 314(18), 1955–1965 (2015)
21. Iannattone, P.A., et al.: Artificial intelligence for diagnosis of acute coronary syndromes: A meta-analysis of machine learning approaches. Can. J. Cardiol. 36(4), 577–583 (2020)
22. Wildi, K., et al.: Misdiagnosis of myocardial infarction related to limitations of the current regulatory approach to define clinical decision values for cardiac troponin. Circulation 131(23), 2032–2040 (2015)
23. Goldstein, B.A., Navar, A.M., Carter, R.E.: Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. Eur. Heart J. 38(23), 1803–1814 (2017)
24. Ward, M.J., et al.: Timeliness of interfacility transfer for ED patients with ST-elevation myocardial infarction. Am. J. Emerg. Med. 33(3), 423–429 (2015)
25. Liu, N., et al.: Prediction of adverse cardiac events in emergency department patients with chest pain using machine learning for variable selection. BMC Med. Inform. Decis. Mak. 14, 75 (2014)
26. Lih, O.S., et al.: Comprehensive electrocardiographic diagnosis based on deep learning. Artif. Intell. Med. 57, 39-43 (2019)
27. Data driven feature selection and machine learning to detect misplaced V1 and V2 chest electrodes when recording the 12-lead electrocardiogram. J. Electrocardiol. 57, 39-43 (2019)
28. Validity of myocardial infarction diagnoses in administrative databases: A systematic review. PLoS ONE 9(3), e92286 (2014)
29. Coloma, P.M., et al.: Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 3(6), e002862 (2013)
30. Bezir, J., et al.: Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam. Clin. Pharmacol. 29(6), 586–591 (2015)
31. Cozzolino, F., et al.: A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. PLoS One 14(7), e0218919 (2019)
32. Ando, T., et al.: Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center. BMC Health Serv. Res. 18(1), 895 (2018)
33. McCormick, N., et al.: Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS One 9(3), e92286 (2014)
34. Guimaraes, P.O., et al.: Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction. JAMA Cardiol. 2(7), 750–757 (2017)
35. Antman, E.M., et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284(7), 835–842 (2000)
36. Granger, C.B., et al.: Predictors of hospital mortality in the global registry of acute coronary events. Arch. Intern. Med. 163(19), 2345–2353 (2003)
37. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). Circulation 126(7), 875–910 (2012)
38. Roffi, M., et al.: 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37(3), 267–315 (2016)
39. Park, K.C., et al.: Cardiac troponins: From myocardial infarction to chronic disease. Cardiovasc. Res. 113(14), 1708–1718 (2017)
40. VanHouten, J.P., et al.: Machine learning for risk prediction of acute coronary syndrome. In: AMIA Annual Symp. Proc, pp. 1940–1949. AMIA, Rockville, MD (2014)
41. Goodacre, S.W., et al.: Evaluation of global registry of acute cardiac events and thrombolysis in myocardial infarction scores in patients with suspected acute coronary syndrome. Am. J. Emerg. Med. 30(1), 37–44 (2012)
42. Chen, T., Guestrin, C.: XGBoost: A scalable tree boosting system. In: Proc. of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, pp. 785–794. ACM Press, New York (2016)
43. Python Package Introduction—xgboost 1.4.0-SNAPSHOT documentation. https://xgboost.readthedocs.io/en/latest/python/python_intro.html. Accessed: 19 Jan 2021
44. xgboost: XGBoost Python Package. https://github.com/dmlc/xgboost. Accessed: 19 Jan 2021
45. sklearn.model_selection.GridSearchCV—scikit-learn 0.24.2 documentation. https://scikit-learn.org/stable/modules/generated/sklearn.model_selection.GridSearchCV.html. Accessed 5 May 2021
46. Adler-Milstein, J., et al.: Electronic health record adoption in US hospitals: the emergence of a digital “advanced use” divide. J. Am. Med. Inform. Assoc. JAMIA 24(6), 1142–1148 (2017)
47. Than, M.P., et al.: Machine learning to predict the likelihood of acute myocardial infarction. Circulation 140(11), 899–909 (2019)
48. Díaz-Garzón, J., et al.: Discordance between ICD-Coded myocardial infarction and diagnosis according to the universal definition of myocardial infarction. Clin. Chem. 63(1), 415–419 (2017)
49. Poldervaart, J.M., et al.: Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department. Int. J. Cardiol. 227, 656–661 (2017)
50. Zheng, W., et al.: Evaluation and comparison of six GRACE models for the stratification of undifferentiated chest pain in the emergency department. BMC Cardiovasc. Disord. 20, 199 (2020)
51. Liu, N., et al.: Clinical scores for risk stratification of chest pain patients in the emergency department: An updated systematic review. J. Emerg. Crit. Care Med. 2(2), 16 (2018)
52. Sidey-Gibbons, J.A.M., Sidey-Gibbons, C.J.: Machine learning in medicine: A practical introduction. BMC Med. Res. Methodol. 19(1), 64 (2019)
53. Mandair, D., et al.: Development of a prediction model for incident myocardial infarction using machine learning applied to harmonized electronic health record data. J. Am. Coll. Cardiol. 75(11_Supplement_1), 194–194 (2020)
54. Gibson, W.J., et al.: Machine learning versus traditional risk stratification methods in acute coronary syndrome: A pooled randomized clinical trial analysis. J. Thromb. Thrombolysis 49(1), 1–9 (2020)
55. Mannil, M., et al.: Texture analysis and machine learning for detecting myocardial infarction in noncontrast low-dose computed tomography: Unveiling the invisible. Invest. Radiol. 53(6), 338–343 (2018)

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Panchavati, S., et al.: Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification. Healthc. Technol. Lett. 8:139–147 (2021). https://doi.org/10.1049/htl2.12017.